Home Healthcare Drugs Polycystic Ovarian Syndrome Treatment Market by Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, and Others), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026

Polycystic Ovarian Syndrome Treatment Market by Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, and Others), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026

Publisher: Allied Market Research
Publication Date: January, 2020
Healthcare / Drugs
Pages: 217
Delivery Format: PDF

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

The global polycystic ovarian syndrome treatment market was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.

Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, medications are used to regulate menstrual cycle and manage symptoms of PCOS.

The polycystic ovarian syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in prevalence of PCOS, rise in awareness among the patient population about PCOS, and increase in popularity of combination therapy drives the market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medication, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth.

The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers . Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS
By Drug Class
• Insulin Sensitizing Agent
• Oral Contraceptive
• Antiandrogens
• Anti-Obesity Drugs
• Others
By Distribution Channel
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers
By Region

• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Allergan plc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Johnson and Johnson
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• SANOFI
• Teva Pharmaceutical Industries

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Merck KGaA
• Ferring BV

Select Plan

1 User License $5,370

5 Users License $6,450

Are you looking for a Consultant?

Email Us

Get a Quote

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$5,370

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed